GILD

$170.330.21%-0.35

プレマーケット: 170.32-0.01 -0.01%

Gilead Sciences Inc (GILD)

Date: O: H: L: C: Vol:

前日終値:

$170.68

開ける：

$169.85

24時間の取引高:

8,876,067

相対出来高:

1.29

時価総額：

$211.27B

収益：

$29.79B

当期純損益:

$9.22B

株価収益率:

23.18

EPS:

$7.35

ネットキャッシュフロー:

$10.23B

1W パフォーマンス:

+7.07%

1M パフォーマンス:

+17.68%

6M パフォーマンス:

+29.38%

1Y パフォーマンス:

+39.56%

1日の値動き範囲:

$0.00$0.00

1週間の範囲:

$156.04$175.65

52週間の値動き範囲:

$114.02$175.65

Gilead Sciences Inc（GILD）会社概要

名前

Gilead Sciences Inc

セクター

Healthcare

産業

Drug Manufacturers - General

電話

(650) 574-3000

住所

333 LAKESIDE DR, FOSTER CITY, CA, USA

職員

17,000

@GileadSciences

次回の収益日

null

最新のSEC提出書

SEC

XでのGILDに関するディスカッション

時価総額

収益

当期純利益

現金流量

EPS

Gilead Sciences Inc (GILD) アップグレードとダウングレード

日付	アクション	アナリスト	評価の変更
2026-07-21	ダウングレード	Leerink Partners	Outperform → Market Perform
2026-07-06	アップグレード	HSBC Securities	Hold → Buy
2026-05-20	アップグレード	Maxim Group	Hold → Buy
2026-03-10	開始されました	Jefferies	Buy
2026-02-20	開始されました	Barclays	Equal Weight
2026-02-11	繰り返されました	Needham	Buy
2026-01-07	Resumed	UBS	Buy
2025-11-24	Resumed	Truist	Buy
2025-11-13	開始されました	Scotiabank	Sector Outperform
2025-08-19	アップグレード	Daiwa Securities	Neutral → Outperform
2025-08-08	アップグレード	Truist	Hold → Buy
2025-07-25	アップグレード	Needham	Hold → Buy
2025-04-22	Resumed	Cantor Fitzgerald	Overweight
2025-03-04	繰り返されました	Oppenheimer	Outperform
2025-02-18	アップグレード	Deutsche Bank	Hold → Buy
2025-02-13	アップグレード	DZ Bank	Hold → Buy
2025-01-10	アップグレード	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Resumed	BofA Securities	Buy
2024-11-15	開始されました	Wolfe Research	Outperform
2024-11-14	開始されました	Citigroup	Buy
2024-11-08	ダウングレード	Maxim Group	Buy → Hold
2024-10-21	アップグレード	Leerink Partners	Market Perform → Outperform
2024-10-17	開始されました	Bernstein	Outperform
2024-10-07	アップグレード	Wells Fargo	Equal Weight → Overweight
2024-07-08	アップグレード	Raymond James	Mkt Perform → Outperform
2024-05-01	繰り返されました	Maxim Group	Buy
2024-04-24	アップグレード	HSBC Securities	Reduce → Hold
2024-02-22	ダウングレード	Truist	Buy → Hold
2023-11-09	開始されました	Deutsche Bank	Hold
2023-09-08	アップグレード	BofA Securities	Neutral → Buy
2023-09-06	開始されました	HSBC Securities	Reduce
2023-07-24	繰り返されました	Barclays	Equal Weight
2023-05-16	アップグレード	BMO Capital Markets	Market Perform → Outperform
2023-04-28	Resumed	Piper Sandler	Overweight
2023-01-03	ダウングレード	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	Resumed	BofA Securities	Neutral
2022-12-09	ダウングレード	DZ Bank	Buy → Hold
2022-10-31	アップグレード	Barclays	Underweight → Equal Weight
2022-10-28	繰り返されました	BMO Capital Markets	Market Perform
2022-10-28	繰り返されました	Cowen	Outperform
2022-10-28	繰り返されました	JP Morgan	Overweight
2022-10-28	繰り返されました	Jefferies	Buy
2022-10-28	アップグレード	Piper Sandler	Neutral → Overweight
2022-10-28	繰り返されました	RBC Capital Mkts	Outperform
2022-10-28	アップグレード	Truist	Hold → Buy
2022-10-28	繰り返されました	Wells Fargo	Equal Weight
2022-10-04	アップグレード	JP Morgan	Neutral → Overweight
2022-07-13	開始されました	Cantor Fitzgerald	Neutral
2022-05-23	開始されました	SVB Leerink	Mkt Perform
2022-02-28	ダウングレード	BMO Capital Markets	Outperform → Market Perform
2022-02-02	繰り返されました	BMO Capital Markets	Outperform
2022-02-02	繰り返されました	BofA Securities	Neutral
2022-02-02	繰り返されました	RBC Capital Mkts	Outperform
2022-02-02	繰り返されました	Truist	Hold
2022-02-02	繰り返されました	Wells Fargo	Equal Weight
2022-01-28	アップグレード	Argus	Hold → Buy
2022-01-06	ダウングレード	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	Resumed	Wells Fargo	Equal Weight
2021-12-06	開始されました	Goldman	Neutral
2021-11-19	アップグレード	BMO Capital Markets	Market Perform → Outperform
2021-11-19	Resumed	Piper Sandler	Neutral
2021-10-20	Resumed	Cowen	Outperform
2021-07-30	繰り返されました	BMO Capital Markets	Market Perform
2021-07-30	繰り返されました	RBC Capital Mkts	Outperform
2021-04-01	アップグレード	Bernstein	Mkt Perform → Outperform
2021-03-30	アップグレード	Redburn	Neutral → Buy
2021-01-19	アップグレード	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	アップグレード	Guggenheim	Neutral → Buy
2020-11-03	Resumed	Morgan Stanley	Equal-Weight
2020-10-28	開始されました	UBS	Neutral
2020-09-30	Resumed	Jefferies	Buy
2020-09-15	アップグレード	Maxim Group	Hold → Buy
2020-07-31	繰り返されました	Credit Suisse	Neutral
2020-07-31	繰り返されました	Morgan Stanley	Equal-Weight
2020-07-31	繰り返されました	Piper Sandler	Overweight
2020-07-31	繰り返されました	RBC Capital Mkts	Outperform
2020-07-31	繰り返されました	SunTrust	Hold
2020-07-31	繰り返されました	Wells Fargo	Equal Weight
2020-07-20	アップグレード	Credit Suisse	Underperform → Neutral
2020-06-03	アップグレード	SVB Leerink	Mkt Perform → Outperform
2020-05-26	アップグレード	SunTrust	Sell → Hold
2020-05-01	ダウングレード	JP Morgan	Overweight → Neutral
2020-05-01	ダウングレード	Raymond James	Outperform → Mkt Perform
2020-05-01	ダウングレード	SunTrust	Hold → Sell
2020-04-27	ダウングレード	UBS	Buy → Neutral
2020-04-20	ダウングレード	BMO Capital Markets	Outperform → Market Perform
2020-04-20	ダウングレード	Wells Fargo	Overweight → Equal Weight
2020-04-17	ダウングレード	CFRA	Hold → Sell

Gilead Sciences Inc (GILD) 財務データ

期間	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
期間終了日	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	29,443.00	28,754.00	27,116.00	27,281.00	27,305.00
Cost of revenue USD (M)	6,234.00	6,251.00	6,498.00	5,657.00	6,601.00
Gross profit USD (M)	-	-	20,618.00	21,624.00	20,704.00
Operating expenses USD (M)	19,421.00	27,092.00	13,013.00	14,294.00	10,786.00
Operating income USD (M)	10,022.00	1,662.00	7,605.00	7,330.00	9,918.00
Income before tax USD (M)	9,796.00	690.00	6,859.00	5,814.00	8,278.00
Income tax expense USD (M)	1,286.00	211.00	1,247.00	1,248.00	2,077.00
Net income USD (M)	8,510.00	480.00	5,613.00	4,566.00	6,201.00
Basic EPS USD/shares	6.84	0.38	4.54	3.66	4.96
Diluted EPS USD/shares	6.78	0.38	4.50	3.64	4.93
Basic weighted shares shares (M)	1,244.00	1,247.00	1,248.00	1,255.00	1,256.00
Diluted weighted shares shares (M)	1,255.00	1,255.00	1,258.00	1,262.00	1,262.00
Selling, general and administrative USD (M)	5,774.00	6,091.00	6,090.00	5,673.00	5,246.00

Gilead Sciences Inc (GILD) インサイダートレーディング

DANIEL O'DAYOct 30 '26
Director
取引
Proposed Sale
コスト
$165.61
#株式
45,881
値 ($)
7,598,352
#株式総数
0
Mercier JohannaOct 15 '26
Chief Comm & Corp Aff Officer
取引
Sale
コスト
$156.22
#株式
3,000
値 ($)
468,660
#株式総数
113,684
JOHANNA MERCIEROct 15 '26
Officer
取引
Proposed Sale
コスト
$156.22
#株式
3,000
値 ($)
468,660
#株式総数
0
Dickinson Andrew DOct 15 '26
Chief Financial Officer
取引
Sale
コスト
$156.22
#株式
3,000
値 ($)
468,660
#株式総数
161,096
ANDREW DICKINSONOct 15 '26
Officer
取引
Proposed Sale
コスト
$156.22
#株式
3,000
値 ($)
468,660
#株式総数
0
O'Day Daniel PatrickOct 01 '26
Chairman & CEO
取引
Sale
コスト
$147.90
#株式
15,000
値 ($)
2,218,508
#株式総数
566,683
ANDREW DICKINSONSep 15 '26
Officer
取引
Proposed Sale
コスト
$145.29
#株式
3,000
値 ($)
435,870
#株式総数
0
Mercier JohannaSep 15 '26
Chief Comm & Corp Aff Officer
取引
Sale
コスト
$144.22
#株式
3,000
値 ($)
432,646
#株式総数
116,684
Dickinson Andrew DSep 15 '26
Chief Financial Officer
取引
Sale
コスト
$145.29
#株式
3,000
値 ($)
435,870
#株式総数
164,096
JOHANNA MERCIERSep 15 '26
Officer
取引
Proposed Sale
コスト
$144.22
#株式
3,000
値 ($)
432,646
#株式総数
0

インサイダートレーディング	関係	日付	取引	コスト	#株式	値 ($)	#株式総数
DANIEL O'DAY	Director	Oct 30 '26	Proposed Sale	$165.61	45,881	7,598,352	0
Mercier Johanna	Chief Comm & Corp Aff Officer	Oct 15 '26	Sale	$156.22	3,000	468,660	113,684
JOHANNA MERCIER	Officer	Oct 15 '26	Proposed Sale	$156.22	3,000	468,660	0
Dickinson Andrew D	Chief Financial Officer	Oct 15 '26	Sale	$156.22	3,000	468,660	161,096
ANDREW DICKINSON	Officer	Oct 15 '26	Proposed Sale	$156.22	3,000	468,660	0
O'Day Daniel Patrick	Chairman & CEO	Oct 01 '26	Sale	$147.90	15,000	2,218,508	566,683
ANDREW DICKINSON	Officer	Sep 15 '26	Proposed Sale	$145.29	3,000	435,870	0
Mercier Johanna	Chief Comm & Corp Aff Officer	Sep 15 '26	Sale	$144.22	3,000	432,646	116,684
Dickinson Andrew D	Chief Financial Officer	Sep 15 '26	Sale	$145.29	3,000	435,870	164,096
JOHANNA MERCIER	Officer	Sep 15 '26	Proposed Sale	$144.22	3,000	432,646	0

Gilead Sciences Inc (GILD) 最新ニュース

Nov 02, 2026

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Benzinga

Nov 02, 2026

Bernstein raises Gilead Sciences stock price target on strong growth - Investing.com

Nov 02, 2026

Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow - Yahoo Finance

Nov 02, 2026

Gilead Sciences, Inc. $GILD Stock Sold by Hennessy Advisors Inc. - MarketBeat

Nov 02, 2026

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? - Zacks Investment Research

Nov 02, 2026

Gilead Sciences (GILD) Maintains Quarterly Dividend Amid Mixed V - GuruFocus

Nov 02, 2026

Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences - BioSpace

Nov 02, 2026

Nov 01, 2026

1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November - The Motley Fool

Nov 01, 2026

Oct 30, 2026

Gilead Sciences, Inc. (GILD) Stock Forecasts - Yahoo Finance

Oct 30, 2026

Gilead Sciences Inc (GILD) Stock Up 3.1% but GF Value Says Overv - GuruFocus

Oct 30, 2026

Gilead Sciences Inc Stock (GILD) Moved Up by 3.83% on Oct 30: What Investors Need To Know - TradingKey

Oct 30, 2026

Gilead: Q3 Earnings Overview; It's Time To Consider Selling After Stellar Year (GILD) - Seeking Alpha

Oct 30, 2026

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth - Zacks Investment Research

Oct 30, 2026

GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks - Zacks Investment Research

Oct 30, 2026

Gilead Sciences, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance

Oct 30, 2026

Gilead Sciences Stock: Why I Remain Bullish After Q3 (NASDAQ:GILD) - Seeking Alpha

Oct 30, 2026

Gilead Sciences (GILD) Reports Strong Q3 2026 Sales Growth, Rais - GuruFocus

Oct 30, 2026

Gilead Sciences Inc (GILD) (Q3 2026) Earnings Call Highlights: Base Business Surges 16% as HIV ... - Yahoo Finance

Oct 30, 2026

Oct 29, 2026

What Gilead Sciences (GILD) Said on Its Q3 Earnings Call - Yahoo Finance

Oct 29, 2026

Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Zacks Investment Research

Oct 29, 2026

Gilead Sciences, Inc. (GIS.F) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 29, 2026

Gilead Sciences, Inc. (GILD.VI) Seasonal returns chart - Yahoo Finance Australia

Oct 29, 2026

Gilead Sciences, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:GILD) 2026-10-29 - Seeking Alpha

Oct 29, 2026

Gilead Sciences, Inc. (GILD) Seasonal returns chart - Yahoo Finance UK

Oct 29, 2026

Gilead Sciences, Inc. (GILD.MX) Seasonal returns chart - Yahoo Finance Australia

Oct 29, 2026

Gilead Sciences, Inc. (GILD) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 29, 2026

Gilead Sciences, Inc. reports results for the quarter ended September 30 - Earnings Summary - TradingView

Oct 29, 2026

Gilead Sciences Q3 2026 Earnings Call Transcript - Benzinga

Oct 29, 2026

How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade - Investor's Business Daily

Oct 29, 2026

A Look at Gilead Sciences Inc (GILD) After 4.0% Gain -- GF Value $107.30 vs Price $165.61 - GuruFocus

Oct 29, 2026

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates - Yahoo Finance

Oct 29, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 29, 2026

Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength - WSJ

Oct 29, 2026

Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations - Yahoo Finance

Oct 29, 2026

Gilead: Q3 Earnings Snapshot - Yahoo Finance

Oct 29, 2026

Gilead hikes full-year sales outlook, quarterly HIV sales rise 18% - Yahoo Finance

Oct 29, 2026

Breakfast News: Brace for an AI Optics Shake-up - The Motley Fool

Oct 29, 2026

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial - GlobeNewswire Inc.

Oct 29, 2026

Should You Invest in the iShares Biotechnology ETF (IBB)? - Zacks Investment Research

Oct 29, 2026

Oct 28, 2026

Gilead Sciences earnings: what to look for from GILD - Yahoo Finance

Oct 28, 2026

Gilead Sciences Q3 2026 Earnings Preview (GILD:NASDAQ) - Seeking Alpha

Oct 28, 2026

Oct 27, 2026

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool

Oct 27, 2026

Gilead to Report Q3 Earnings: How Should You Play the Stock Now? - Zacks Investment Research

Oct 27, 2026

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Oct 27, 2026

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Zacks Investment Research

Oct 27, 2026

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - Zacks Investment Research

Oct 27, 2026

Gilead Sciences, Inc. (GIS.F) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 27, 2026

Is Gilead Stock Increasing Your Market Risk? - Trefis

Oct 27, 2026

Oct 26, 2026

What Would A Biktarvy Slowdown Do To Gilead Stock? - Trefis

Oct 26, 2026

Gilead Sciences Q3 2026 Earnings Preview — October 29, Street Expects $2.21 EPS - AlphaStreet

Oct 26, 2026

GILDに類似